---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-026636"
form_type: "8-K"
ticker: "INGN"
cik: "0001294133"
company_name: "Inogen Inc"
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:27:17.393460+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inogen Q4 revenue up 5.5% to $80.1M; full-year revenue up 6.4%; operating loss narrows significantly

## Summary
- Q4 revenue $80.1M (+5.5% YoY); gross margin 45.3% (vs 37.1% YoY) on lower raw material costs and efficiencies.
- Q4 GAAP net loss $9.8M improved from $26.6M; adjusted net loss $5.8M; adjusted EBITDA negative $3.6M.
- Full-year 2024 revenue $335.7M (+6.4%); operating loss $42.5M (improved from $109.4M); cash $117.4M, no debt.
- Company provides 2025 growth outlook; announced strategic collaboration with Yuwell to expand product portfolio and global reach.
- Pending U.S. introduction of Simeox airway clearance therapy highlighted as key future growth driver.

## SEC filing metadata
- accession: 0000950170-25-026636
- form_type: 8-K
- ticker: INGN
- cik: 0001294133
- company_name: Inogen Inc
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1294133/000095017025026636/0000950170-25-026636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1294133/000095017025026636/ingn-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-026636
- JSON: https://secwatch.observer/filing/0000950170-25-026636.json
- Plain text: https://secwatch.observer/filing/0000950170-25-026636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.